Cubist starts another Cidecin Phase III

CBST began an open-label Phase III trial of its Cidecin daptomycin infusion in patients with infective endocarditis (IE) and bacteremia caused by Staphylococcus aureus. The primary endpoint of the trial is a non-inferior clinical success rate for Cidecin compared to conventional therapy of nafcillin or vancomycin. ...